gemfibrozil has been researched along with Lipid Metabolism, Inborn Error in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brousseau, ME | 1 |
| O'Connor, JJ | 1 |
| Ordovas, JM | 1 |
| Collins, D | 1 |
| Otvos, JD | 1 |
| Massov, T | 1 |
| McNamara, JR | 1 |
| Rubins, HB | 1 |
| Robins, SJ | 1 |
| Schaefer, EJ | 1 |
| Glueck, CJ | 1 |
| Speirs, J | 1 |
| Tracy, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol[NCT00283335] | Phase 3 | 2,531 participants (Actual) | Interventional | 1991-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for gemfibrozil and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
Topics: Alleles; Apolipoproteins; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; C | 2002 |
1 other study available for gemfibrozil and Lipid Metabolism, Inborn Error
| Article | Year |
|---|---|
Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; | 1990 |